Effects of atorvastatin treatment on sICAM-1 and plasma nitric oxide levels in hypercholesterolemic subjects

Clinical and Applied Thrombosis/Hemostasis

Volumn 8, Issue 3, 2002, Pages 257-263

  Sardo, Maria A ^a   Castaldo, Maria ^a   Cinquegrani, Maurizio ^a   Bonaiuto, Michele ^a   Maesano, Antonella ^a   Versace, Antonio ^a   Spadaro, Miriam ^a   Campo, Salvatore ^a   Nicocia, Giacomo ^a   Altavilla, Domenica ^a   Saitta, Antonino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Atherosclerosis; Atorvastatin; Endothelial activation; Hypercholesterolemia; Nitric oxide; SICAM 1

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTERY ENDOTHELIUM; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0036658167     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960200800310     Document Type: Article

References (27)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801.
2. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22 (suppl 4):S1.
3. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolemia. Lancet 1992;340:1430.
4. Celermajer DS. Endothelial dysfunction: Does it matter? It is reversible? J Am Coll Cardiol 1997;30:325.
5. Hackman A, Abe Y, Insull W Jr, et al. Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996;93:1334.
6. Hwang SJ, Ballantyne CM, Sharrett R, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997;96:4219.
7. Harrison DG. Cellular and molecular mechanism of endothelial cell dysfunction. J Clin Invest 2000;105:1631.
8. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: Physiology and pathophysiology and pharmacology. Pharmacol Rev 1991;43:109.
9. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to the vascular endothelium. Lancet 1987;2:1057.
10. Garg UC, Hassid A. Nitric oxide generating vasodilators and 8-bromo-cyclic GMP inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1974.
11. Spiecker M, Darius H, Kaboth K, et al. Differential regulation of endothelial cell adhesion molecules expression by nitric oxide donors and antioxidants. J Leuk Biol 1998;63:732.
12. Muenzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz 1997;22:158.
13. Tanaka S, Yashiro A, Nakashima Y, et al. Plasma nitrite/nitrate level is inversely correlated with plasma low-density lipoprotein cholesterol level. Clin Cardiol 1997;20:361.
14. Rosselli M, Inthur B, Keller PJ, et al. Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17β-estradiolo and norethisteronre acetate. A two-year follow-up study. Hypertension 1995;25 (part 2):848.
15. Feron O, Dessy C, Moniotte S, et al. Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Invest 1999;103:879.
16. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993;91:2545.
17. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG- coenzyme A reductase inhibitor improves endothelial function within 1 month. Circulation 1997;95:1126.
18. - levels in patients with hypercholesterolemia. Atherosclerosis 1996;127:43.
19. Feron O, Dessy C, Desager JP, Balligand JL. Hydroxy methyl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001;103:113.
20. Sardo MA, Castaldo M, Cinquegrani M, et al. Effects of simvastatin on sICAM-1 and sE-selectin levels in hypercholesterolemia subjects. Atherosclerosis 2001;155:143.
21. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499.
22. Green LC, Wagner DA, Glogowski J, et al. Analysis of nitrite and (15N) nitrate in biological fluids. Ann Biochem 1982;126:131.
23. Kureishi Y, Luo Z, Shijima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase AKT and promotes angiogenesis in normocholesterolemic animals. Nature Med 2000;6:1004.
24. Wagner AH, Kohler T, Rucksholoss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscl Thromb Vasc Biol 2000;20:61.
25. Huie RE, Padmaja S. Reaction of nitric oxide with superoxide anion. Free Radical Res Commun 1993;18:195.
26. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as widely used messengers in the activation of the NF-κB transcription factor and HYV-1. Eur Mol Biol Organ J 1991;10:2247.
27. De Caterina R, Libby P, Peng H-B, et al. Nitric oxide decreases cytokine-induced endothelial activation. J Clin Invest 1995;96:60.